Dry Age Related Macular Degeneration (AMD) Market Report 2026

The dry age related macular degeneration (amd) market size has grown strongly in recent years. It will grow from $4.89 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to aging population growth, ophthalmology clinic expansion, vitamin-based therapy adoption, retinal imaging advancements, vision loss awareness.

The dry age related macular degeneration (amd) market size is expected to see strong growth in the next few years. It will grow to $7.36 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to novel therapeutic pipeline development, precision ophthalmology, ai-based retinal diagnostics, preventive eye care programs, clinical trial investments. Major trends in the forecast period include growing focus on early disease detection, increased use of nutritional supplement therapies, expansion of research on disease-modifying drugs, rising adoption of advanced retinal imaging, increasing patient awareness and screening.

The growing geriatric population is expected to drive the growth of the dry age-related macular degeneration (AMD) market in the coming years. The geriatric population includes individuals aged 65 years and older who experience age-related physiological changes, increasing their demand for healthcare and vision-care services. This population is expanding due to longer life expectancy, improved management of chronic diseases, advancements in medical technology, and broader access to geriatric care globally. The dry AMD market supports this trend by providing targeted therapies and management solutions that help slow retinal degeneration and preserve vision in older adults. For instance, in July 2023, according to the United Nations, a US-based intergovernmental organization, the global population aged 65 years and older reached 0.77 billion in 2022 and is expected to approach 1 billion by 2030. Therefore, the increasing geriatric population is fueling the growth of the dry AMD market.

Major companies in the dry age-related macular degeneration (AMD) market are focusing on developing advanced technologies such as light delivery systems to stimulate retinal cells, enhance visual function, and potentially slow disease progression. Light delivery systems are therapeutic devices designed to deliver controlled wavelengths of light to targeted retinal tissues, activating cellular activity and supporting retinal health through non-invasive photobiomodulation. For instance, in January 2024, LumiThera Inc., a US-based medical device company, launched photobiomodulation therapy for dry AMD using the Valeda Light Delivery System, the first FDA-approved treatment for vision loss associated with dry AMD. The system employs multi-wavelength light (590 nm, 660 nm, and 850 nm) to stimulate retinal cells, and LumiThera initiated the EUROLIGHT registry study to collect long-term outcomes, with treatments typically administered in nine sessions over three to four weeks.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to strengthen its presence in the ophthalmology market by accelerating the development of novel therapies for retinal diseases and improving patient outcomes globally. IVERIC Bio Inc. is a US-based biotechnology company that develops drugs and therapies for age-related macular degeneration and other retinal conditions.

Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.

North America was the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in the dry age related macular degeneration (amd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry age related macular degeneration (amd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dry amd market by increasing costs of imported diagnostic imaging systems, ophthalmic drugs, and nutritional supplements. Hospitals and eye care centers in developed regions are most affected due to dependence on imported equipment. These tariffs elevate treatment costs by increasing procurement expenses for advanced imaging diagnostics and therapeutic products, potentially affecting patient affordability and treatment uptake. However, they support domestic manufacturing of ophthalmic products and imaging devices, encouraging local production, regional supply chain development, and improved availability of cost-effective dry AMD treatment solutions over time.

The dry age related macular degeneration (amd) market research report is one of a series of new reports that provides dry age related macular degeneration (amd) market statistics, including dry age related macular degeneration (amd) industry global market size, regional shares, competitors with a dry age related macular degeneration (amd) market share, detailed dry age related macular degeneration (amd) market segments, market trends and opportunities, and any further data you may need to thrive in the dry age related macular degeneration (amd) industry. This dry age related macular degeneration (amd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dry age-related macular degeneration (AMD) is a progressive eye disorder marked by the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. It is managed and its progression slowed through treatments such as vitamins, nutritional supplements, and emerging pharmaceutical therapies.

The main stages of dry age-related macular degeneration (AMD) are early AMD, intermediate AMD, and late AMD. Early AMD is the initial stage of this common eye condition, primarily affecting older adults and causing changes in the retina, specifically the macula, which is responsible for central vision. It can occur in different age groups, including those above 40 years, 60 years, and 75 years. Treatments are administered through various routes, including oral and injectable forms, and are used by end users such as hospitals and clinics, diagnostic centers, and academic and research institutes.

The dry age related macular degeneration (AMD) market consists of sales of syfovre, zimura, visudyne, and alk-001. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.